



FOR IMMEDIATE RELEASE

October 16, 2026

ASOP Global Warns Proposed Peptide Policy Won't Stop Illegal Online Sales

WASHINGTON, D.C. (October 16, 2026) — According to the Office of Management and Budget (OMB), the U.S. Department of Health and Human Services (HHS) appears to be advancing an “interim access policy” [Notice](#) that would allow 503A compounding pharmacies to compound unproven peptides such as BPC-157. Proponents, including some within the Administration, argue that expanding access through compounding pharmacies could reduce harm because consumers are already purchasing these substances through the gray market.

But this approach risks confusing expanded access with effective action against illegal sellers. [Data](#) from the [Alliance for Safe Online Pharmacies \(ASOP Global\) Foundation](#) show the scale of the existing online market and underscore why changes to compounding policy alone are unlikely to eliminate illicit sales or the risks they pose to consumers.

Since July, the ASOP Global Foundation’s [Rx Watchdog](#) platform has tracked 20,982 online listings for emerging peptide molecules across 330 websites. More than 15,500 listings are for four of the six peptides that the U.S. Food and Drug Administration’s (FDA) advisory panel voted to advance: BPC-157 (8,807), TB-500 (2,645), MOTS-c (2,323), and KPV (1,755). These listings appear on websites outside the licensed pharmacy system, and changes to compounding policy will not, on their own, address these sellers or remove their listings.

In July, ASOP [urged](#) the FDA’s Pharmacy Compounding Advisory Committee to reject all seven nominated peptides, citing insufficient evidence of safety, effectiveness, product quality, and appropriate oversight. ASOP’s position is consistent with concerns raised by FDA scientists about the available evidence for these substances.

“Calling this a fix for the gray market gets it backwards,” said Dr. Leigh Verbois, Board Chair of ASOP Global and former Director of the FDA’s Office of Drug Security, Integrity and Response. “Online sellers offering these peptides aren’t pharmacies, and simply changing compounding rules won’t take a single one offline. Patients deserve evidence before access, and enforcement against the illegal sellers already operating online.”

Learn more at buysaferx.pharmacy and asopfoundation.pharmacy.

###

About ASOP Global

The Alliance for Safe Online Pharmacies (ASOP Global), a 501(c)(4) non-profit organization headquartered in Washington, D.C., with activities in the U.S., Canada, Europe, Latin America, and Asia, is dedicated to

protecting consumers around the world, ensuring safe access to medications, and combating illegal online drug sellers. Learn more at buysaferx.pharmacy.